Lv3
330 积分 2023-05-06 加入
15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study
4天前
已完结
Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes
4天前
已完结
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS
4天前
已完结
Safety and Efficacy of the Combination of Azacitidine with Venetoclax After Hypomethylating Agent Failure in Higher-Risk Myelodysplastic Syndrome
4天前
待确认
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
11天前
已完结
Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends
11天前
已完结
Management of elderly and unfit patients with chronic lymphocytic leukemia
13天前
已完结
Secular trend in disease burden of leukemia and its subtypes in China from 1990 to 2019 and its projection in 25 years
20天前
已完结
Secular trend in disease burden of leukemia and its subtypes in China from 1990 to 2019 and its projection in 25 years
20天前
已完结
Secular trend in disease burden of leukemia and its subtypes in China from 1990 to 2019 and its projection in 25 years
26天前
已完结
皖公网安备34019202002308
